Legal Issue for Securities Exchange and Medical Contracts
Keywords:
Laws, securities exchange, medical contracts, legal, capital market, risk disclosure, treatment, judicial precedent, violation, controlAbstract
Securities exchange is an important issue for legal consideration in capital market and securities laws. The overlapping between for securities exchange and medical contracts is an interesting issue in both legal and medical aspects. Basically, the duty of risk disclosure in both securities exchange and medical treatment contracts is an important topic for discussion. In addition, the details for examining during judicial precedent are also important issues. The good management of legal control is interesting. Also, the proper management of violation of the legal control should also be discussed.
References
1. Iijima Y. Risk disclosure in securities exchange and medical treatment contracts. Nagoya J Med Sci. 2009 Feb;71(1–2):63–9.
2. Brody H, Bonham VL Jr. Gag rules and trade secrets in managed care contracts. Ethical and legal concerns. Arch Intern Med. 1997 Oct 13;157(18):2037–43.
3. Pellegrino ED. Interests, obligations, and justice: some notes toward an ethic of managed care. J Clin Ethics. 1995 Winter;6(4):312–7.
4. Miles SH, Koepp R. Comm ents on the AMA report "Ethical issues in managed care". J Clin Ethics. 1995 Winter;6(4):306–11.
5. Pellegrino ED. Managed care: an ethical reflection. Christ Century. 1998 Aug 12 – 19;115(22):748–51.
6. Pellegrino ED. Managed care and managed competition: some et hical reflections. Calyx. 1994 Fall;4(4):1–5.
7. Capron AM, Brock DW, Cassell EJ. Containing health care costs: ethical and legal implications of changes in the methods of paying physicians. Case West Reserve Law Rev. 1985 –1986;36(4):708– 77.
8. Howe EG. Managed care: "new moves," moral uncertainty, and a radical attitude. J Clin Ethics. 1995 Winter;6(4):290–305.
9. King NM. Ethical and legal barriers to futility policies. N C Med J. 1995 Sep;56(9):444–8.
10. Zoloth-Dorfman L, Rubin SB. "Medical futility." Managed care a nd the powerful new vocabulary for clinical and public policy discourse. Healthc Forum J. 1997 Mar-Apr;40(2):28–33. JCMSL (2019) 1–4 © Law Journals 2019. All Rights Reserved Page 4
11. Reece RL. Bumps on the managed care road: the search for an alternative model to reduce collisions between HMOs, physicians, and patients. M anag Care Q. 2000 Summer;8(3):27–33.
12. Collier R. Nominee to lead US health care accused of insider trading. CMAJ. 2017 Feb 6;189(5):E221.
13. Kesselheim AS, Sinha MS, Joffe S. Physicians and Insider Trading. JAMA Intern Med. 2015 Dec;175(12):1955–9.
14. Ledford H. Insider trading sparks concerns. Nature. 2013 Jan 17;493(7432):280–1.
15. Jiang H, Panarelli J. Insider Trading. J Pediatr Ophthalmol Strabismus. 2016 Jul 1;53(4):203–4.
16. Morgan PW. Technology transfer —the rôle of venture capital. J Med Eng Technol. 1987 Sep-Oct;11(5):249–54.
17. Ferguson JR. Biomedical research and insider trading. N Engl J Med. 1997 Aug 28;337(9):631–4.
18. Dunmire SN. Health care delivery systems in review. J Med Pract Manage. 1988 Winter;3(3):184–6.
19. Kesselheim AS, Sinha MS, Joffe S. Physicians and Insider Trading. JAMA Intern Med. 2015 Dec;175(12):1955–9.
20. Weeks WB, Nells T, Wallace AE. Transfer of risk: "right to sue" legislation and managed care organization stock performance. J Health Care Finance. 2001 Fall;28(1):16–24.
21. Pauly MV, Hillman AL, Furukawa MF, McCullough JS. HMO behavior and stock market valuation: what does Wall Street reward and punish? J Health Care Finance. 2001 Fall;28(1):7–15.
22. Horwich A. The clinical trial research participant as an inside trader: a legal and policy analysis. J Health Law. 2006 Winter;39(1):77–116.
23. Ferguson JR. Biomedical research and insider trading. N Engl J Med. 1997 Aug 28;337(9):631–4. Cite this Article Rujittika Mungmunpuntipantip, Viroj Wiwnaitkit. Legal is sue for Securities Exchange and Medical Contracts. Journal of Capital Market and Securities Law . 2019; 2(2): 1–4p.
